Synapse - Heather Landau

Results (151)

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation

Journal Article

Prockop, S.; Doubrovina, E.; Suser, S.; Heller, G.; Barker, J.; Dahi, P.; Perales, M. A.; Papadopoulos, E.; Sauter, C.; Castro-Malaspina, H.; more...
Journal of Clinical Investigation (2020)

Fulltext@MSK | Save

Pilot study of bortezomib and dexamethasone pre- and post-risk-adapted autologous stem cell transplantation in AL amyloidosis

Journal Article

Landau, H.; Lahoud, O.; Devlin, S.; Lendvai, N.; Chung, D. J.; Dogan, A.; Landgren, C. O.; Giralt, S.; Hassoun, H.
Biology of Blood and Marrow Transplantation (2020)

Fulltext@MSK | Save

Difference in involved and uninvolved free light chain (dFLC) of less than 1mg/DL early post risk adapted melphalan and autologous stem cell transplantation (RA-ASCT) predicts renal response at 1 year in light chain (AL) amyloidosis

Meeting Abstract

Purvey, S.; Seier, K.; Devlin, S. M.; Ruiz, J. D.; Maloy, M. A.; Shah, G. L.; Hassoun, H.; Giralt, S. A.; Landau, H. J.
Blood (2019)

Fulltext@MSK | Save

Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
Blood (2019)

Fulltext@MSK | Save

Microbiota injury in auto-HCT is frequent, occurs across geography, and is comparable to that observed in allo-HCT

Meeting Abstract

Khan, N.; Peled, J. U.; Gomes, A.; Devlin, S. M.; Rondon Clavo, C.; Clurman, A.; Slingerland, J.; Slingerland, A. E.; Maloy, M. A.; Sung, A. D.; more...
Biology of Blood and Marrow Transplantation (2019)

Fulltext@MSK | Save

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
Blood (2019)

Fulltext@MSK | Save

Interleukin-6 (IL-6) blockade with siltuximab peri-autologous hematopoietic stem cell transplantation (AHCT) may reduce symptom burden by altering the cytokine milieu in older patients with multiple myeloma (MM)

Meeting Abstract

Shah, G.; Holder, J.; Cho, S.; Murata, K.; Devlin, S.; Hoover, E.; Chung, D.; Dahi, P.; Lahoud, O.; Scordo, M.; more...
Clinical Lymphoma, Myeloma and Leukemia (2019)

Fulltext@MSK | Save

Successful pharmacokinetic (PK)-directed dosing of Evomela® (propylene glycol free melphalan, PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) patients undergoing autologous hematopoietic stem cell transplant (AHCT)

Meeting Abstract

Shah, G.; Lin, A.; Grumley, A.; Kamrowski, A.; Schofield, R.; Devlin, S.; Bhatt, V.; Proli, A.; Chung, D.; Dahi, P.; more...
Clinical Lymphoma, Myeloma and Leukemia (2019)

Fulltext@MSK | Save

Dysgeusia is associated with higher melphalan pharmacokinetic levels and results in poorer caloric intake and worse symptom burden after autologous stem cell transplantation for multiple myeloma